Independent directory Public ClinicalTrials.gov records United States
Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 21, 2026, 6:09 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 228 matching trials from the live ClinicalTrials.gov search.
Conditions
Leukemia, Lymphoma
Interventions
filgrastim, cyclophosphamide, etoposide, peripheral blood stem cell transplantation, radiation therapy
Biological · Drug · Procedure + 1 more
Lead sponsor
Northwestern University
Other
Eligibility
Up to 65 Years
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1999 – 2003
U.S. locations
1
States / cities
Chicago, Illinois
Conditions
Degenerative Disc Disease, Spinal Stenosis, Spondylolisthesis
Interventions
nanOss Bioactive Bone void filler, Interbody FCage
Device
Lead sponsor
Pioneer Surgical Technology, Inc.
Industry
Eligibility
18 Years and older
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2013
U.S. locations
7
States / cities
Beverly Hills, California • La Jolla, California • Chicago, Illinois + 4 more
Conditions
Breast Cancer
Interventions
high dose chemo then auto hematopoietic cell transplant
Procedure
Lead sponsor
Stanford University
Other
Eligibility
19 Years to 70 Years
Enrollment
99 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1996 – 2005
U.S. locations
1
States / cities
Stanford, California
Conditions
Multiple Myeloma
Interventions
BHV-1100 plus cytokine induced memory-like (CIML) NK cells plus IVIG and low dose IL-2
Combination Product
Lead sponsor
Biohaven Pharmaceuticals, Inc.
Industry
Eligibility
18 Years to 75 Years
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2025
U.S. locations
1
States / cities
Boston, Massachusetts
Conditions
Leukemia
Interventions
busulfan, cyclophosphamide, filgrastim, recombinant interferon alfa, in vitro-treated peripheral blood stem cell transplantation, peripheral blood stem cell transplantation, radiation therapy
Drug · Procedure
Lead sponsor
Masonic Cancer Center, University of Minnesota
Other
Eligibility
18 Years to 65 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2000
U.S. locations
1
States / cities
Minneapolis, Minnesota
Conditions
Burn, Thermal
Interventions
StrataGraft Skin Tissue, Autograft
Biological · Procedure
Lead sponsor
Stratatech, a Mallinckrodt Company
Industry
Eligibility
18 Years and older
Enrollment
71 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
16
States / cities
Mobile, Alabama • Phoenix, Arizona • Orange, California + 13 more
Conditions
Waldenstrom Macroglobulinemia
Interventions
DT PACE + Rituxan
Drug
Lead sponsor
University of Arkansas
Other
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2008
U.S. locations
1
States / cities
Little Rock, Arkansas
Conditions
Lumbar Spine Disease, Lumbar Spondylolisthesis, Lumbar Spine Instability, Lumbar Spondylosis, Degenerative Disc Disease
Interventions
OSTEOAMP, Infuse
Other · Device
Lead sponsor
Bioventus LLC
Industry
Eligibility
21 Years to 80 Years
Enrollment
101 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
9
States / cities
New Haven, Connecticut • Wichita, Kansas • Paducah, Kentucky + 6 more
Conditions
Multiple Myeloma
Interventions
Melphalan HCl for injection (propylene glycol free)
Drug
Lead sponsor
Medical College of Wisconsin
Other
Eligibility
18 Years and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
1
States / cities
Milwaukee, Wisconsin
Conditions
Acute Myelogenous Leukemia (AML), Chronic Myelogenous Leukemia (CML), Acute Lymphoblastic Leukemia (ALL), Myelodysplastic Syndrome (MDS), B Cell Malignancies
Interventions
WT1 derived peptides
Biological
Lead sponsor
Michael Morse, MD
Other
Eligibility
18 Years and older
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2013
U.S. locations
1
States / cities
Durham, North Carolina
Conditions
B-cell Lymphoma, Non-Hodgkin's Lymphoma
Interventions
Bexxar
Drug
Lead sponsor
University of Pennsylvania
Other
Eligibility
18 Years to 75 Years
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2015
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Conditions
Non Hodgkin Lymphoma, Follicular Lymphoma, Indolent Lymphoma, B-cell Lymphoma, Transformed Lymphoma, Marginal Zone Lymphoma, Waldenstrom Macroglobulinemia, Small Lymphocytic Lymphoma, Lymphoplasmacytic Lymphoma
Interventions
Zydelig
Drug
Lead sponsor
University of Maryland, Baltimore
Other
Eligibility
18 Years and older
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2024
U.S. locations
3
States / cities
Miami, Florida • Baltimore, Maryland • Milwaukee, Wisconsin
Conditions
Mantle Cell Lymphoma
Interventions
R-CHOP-14R-HIDAC,followed by RIT/HDT/ASCR.
Other
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years to 70 Years
Enrollment
96 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2023
U.S. locations
5
States / cities
Basking Ridge, New Jersey • Commack, New York • New York, New York + 2 more
Completed Phase 2Phase 3 Interventional Results available

Autologous Transplant for Multiple Myeloma

NCT00177047
Conditions
Multiple Myeloma
Interventions
Stem Cell Transplant, Cyclophosphamide + Mesna, Melphalan, Granulocyte-colony stimulating factor
Procedure · Drug · Biological
Lead sponsor
Masonic Cancer Center, University of Minnesota
Other
Eligibility
18 Years to 75 Years
Enrollment
363 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2020
U.S. locations
1
States / cities
Minneapolis, Minnesota
Conditions
Surgical Wound, Trauma Wound, Autografts, Partial-thickness Burn, Partial Thickness Wounds
Interventions
PermeaDerm Biosynthetic Wound Matrix, Frozen Human Cadaveric Allograft (FHCA)
Device
Lead sponsor
Avita Medical
Industry
Eligibility
Not listed
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
13
States / cities
Phoenix, Arizona • Washington D.C., District of Columbia • Atlanta, Georgia + 10 more
Conditions
Degenerative Disc Disease
Interventions
TLIF with a PEEK Spacer System and XIA Spinal System
Device
Lead sponsor
Olympus Biotech Corporation
Industry
Eligibility
18 Years to 80 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2010
U.S. locations
10
States / cities
Los Angeles, California • San Diego, California • Durango, Colorado + 7 more
Completed Not applicable Interventional

Human Ovarian Autotransplantation

NCT01403675
Conditions
Ovarian Autotransplantation Using Cryopreserved Ovarian Tissue in Women Treated for Cancer
Interventions
Ovarian autotransplantation
Procedure
Lead sponsor
Samuel Kim, MD
Other
Eligibility
18 Years to 40 Years · Female only
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2014
U.S. locations
1
States / cities
Kansas City, Kansas
Conditions
Breast Cancer
Interventions
trastuzumab, carboplatin, carmustine, cisplatin, cyclophosphamide, thiotepa, peripheral blood stem cell transplantation
Biological · Drug · Procedure
Lead sponsor
Beth Israel Deaconess Medical Center
Other
Eligibility
18 Years to 65 Years · Female only
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000
U.S. locations
2
States / cities
Boston, Massachusetts • Hackensack, New Jersey
Conditions
Wounds and Injury
Interventions
Recell, Control
Device · Procedure
Lead sponsor
Rubin, J. Peter, MD
Other
Eligibility
18 Years and older
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
1
States / cities
Bethesda, Maryland
Conditions
Multiple Myeloma
Interventions
Lenalidomide, lenalidomide, bortezomib and dexamethasone
Drug
Lead sponsor
National Heart, Lung, and Blood Institute (NHLBI)
NIH
Eligibility
Up to 70 Years
Enrollment
758 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2018
U.S. locations
54
States / cities
Tucson, Arizona • Duarte, California • La Jolla, California + 46 more
Conditions
Refractory Multiple Myeloma, Stage II Multiple Myeloma, Stage III Multiple Myeloma
Interventions
melphalan, amifostine trihydrate, peripheral blood stem cell transplantation, fluorescence in situ hybridization, bone marrow ablation with stem cell support
Drug · Procedure · Genetic
Lead sponsor
Fred Hutchinson Cancer Center
Other
Eligibility
18 Years to 70 Years
Enrollment
130 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2005
U.S. locations
4
States / cities
Los Angeles, California • Rochester, New York • Seattle, Washington
Conditions
Multiple Myeloma
Interventions
Cyclophosphamide, Etoposide, Melphalan, Carmustine, Filgrastim
Drug
Lead sponsor
Stanford University
Other
Eligibility
18 Years to 75 Years
Enrollment
102 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2010
U.S. locations
1
States / cities
Stanford, California
Conditions
Glioma, Malignant, Glioblastoma, Glioblastoma Multiforme, Glioblastoma Multiforme, Adult, High Grade Glioma, GBM, Brain Cancer
Interventions
Tissue autograft of pedicled temporoparietal fascial (TPF) or pericranial flap to bypass the blood brain barrier (BBB)
Procedure
Lead sponsor
Northwell Health
Other
Eligibility
18 Years and older
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2029
U.S. locations
1
States / cities
New York, New York
Conditions
Multiple Myeloma
Interventions
Granulocyte colony-stimulating factor plus plerixafor, Granulocyte colony-stimulating factor plus placebo
Drug
Lead sponsor
Genzyme, a Sanofi Company
Industry
Eligibility
18 Years to 78 Years
Enrollment
302 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2008
U.S. locations
37
States / cities
Phoenix, Arizona • Little Rock, Arkansas • Duarte, California + 28 more